Cancer clinical trials in the region Normandie

253 currently recruiting clinical trials
Region Normandie

Phase 3 Endometrial cancer #NCT06340568 #2023-507525-42-00
Required histologic sub types
Endometrioid adenocarcinoma Serous adenocarcinoma Clear cell carcinoma Dedifferentiated and undifferentiated endometrial ... Carcinosarcoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None 1
Required previous treatments at localized stage
Immunotherapy Chemotherapy
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Immunotherapy Chemotherapy
Excluded previous treatments at localized stage
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Antibody Drug Conjugates (ADC)
8 recruiting sites
BioNTech SE
Phase 3 Prostate cancer #NCT06952803 #2024-513586-39-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized Biochemical recurrence
Required genetic anomalies
BRCA 1/2
Required previous treatments at localized stage
Radiotherapy Hormone therapy
Excluded previous treatments at localized stage
Immunotherapy Chemotherapy Targeted therapy
19 recruiting sites
AstraZeneca
Phase 3 Endometrial cancer #NCT06989112 #2023-508056-19-00
Required histologic sub types
Endometrioid adenocarcinoma Serous adenocarcinoma Clear cell carcinoma Dedifferentiated and undifferentiated endometrial ... Carcinosarcoma
Required FIGO stages
Stage III Stage IV
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Immunotherapy Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Antibody Drug Conjugates (ADC)
10 recruiting sites
Phase 3 Lung cancer #NCT06417814 #2024-511362-37-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at localized stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Immunotherapy Chemotherapy
14 recruiting sites
AstraZeneca
Phase 3 Breast cancer #NCT05952557 #2023-504031-41-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery Chemotherapy Radiotherapy Hormone therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
21 recruiting sites
AstraZeneca
Phase 3 Lymphoma CLL & Richter's syndrome #NCT06973187 #2025-522860-34-00
Required histologic types
B cell lymphoma CLL (Chronic Lymphocytic Leukemia)
Required histologic sub types
Lymphocytic lymphoma
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Targeted therapy
Excluded previous treatments
Systemic Treatment-Naive
8 recruiting sites
BeOne Medecines
Phase 3 Breast cancer #NCT06195709 #2023-506282-66-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Targeted therapy Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Chemotherapy Car-T Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)
10 recruiting sites
Institut Curie
Phase 3 Lymphoma CLL & Richter's syndrome #NCT06943872 #2024-517131-52-00
Required histologic types
B cell lymphoma CLL (Chronic Lymphocytic Leukemia)
Required histologic sub types
Lymphocytic lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
9 recruiting sites
Phase 3 Lung cancer #NCT06908993 #2024-519971-25-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
MET
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
Excluded genetic anomalies
ALK BRAF EGFR HER2 KRAS non G12C RET ROS-1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Targeted therapy
32 recruiting sites
Intergroupe Francophone de Cancérologie Thoracique
Phase 3 Colon cancer Rectal cancer #NCT06293625
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Required genetic anomalies
MSS/pMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded genetic anomalies
MSI/dMMR
57 recruiting sites
CHU Dijon